<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17915166</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>López Rodríguez, M</dc:author>
<dc:author>Gómez Cerezo, J</dc:author>
<dc:author>García Arias, M</dc:author>
<dc:description xml:lang="en">Tumor necrosis factor (TNFalpha) is a main mediator in the inflammatory answer of many diseases. The anti-TNFalpha antibodies (infliximab, etanercept, adalimumab) block their action, preventing the inflammatory answer and the damage it produces. In this paper, we review the treatment of some diseases in which these drugs are experimentally used. These are: ulcerative colitis, sarcoidosis, graft-versus-host disease, adult Still's disease, some systemic vasculitis, systemic lupus erythematosus and Behçet disease.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2007 Oct </dc:date>
<dc:title xml:lang="es">Terapia biológica con anticuerpos anti factor de necrosis tumoral, ampliando el espectro de sus indicaciones?</dc:title>
<dc:title xml:lang="en">[Biological therapy with anti-TNF antibodies. Extending the spectrum of its indications?].</dc:title>
<dc:publisher>Revista clinica espanola</dc:publisher>
</metadata>
</record>
</pubmed-document>
